Cargando…

Lovastatin, not Simvastatin, Corrects Core Phenotypes in the Fragile X Mouse Model

The cholesterol-lowering drug lovastatin corrects neurological phenotypes in animal models of fragile X syndrome (FX), a commonly identified genetic cause of autism and intellectual disability (ID). The therapeutic efficacy of lovastatin is being tested in clinical trials for FX; however, the struct...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muscas, Melania, Louros, Susana R., Osterweil, Emily K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society for Neuroscience 2019
Materias:	New Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6565377/ https://www.ncbi.nlm.nih.gov/pubmed/31147392 http://dx.doi.org/10.1523/ENEURO.0097-19.2019

Ejemplares similares

A Differential Effect of Lovastatin versus Simvastatin in Neurodevelopmental Disorders
por: Muscas, Melania, et al.
Publicado: (2020)

Cell-Type-Specific Translation Profiling Reveals a Novel Strategy for Treating Fragile X Syndrome
por: Thomson, Sophie R., et al.
Publicado: (2017)

Differences Between Lovastatin and Simvastatin Hydrolysis in Healthy Male and Female Volunteers: Gut Hydrolysis of Lovastatin is Twice that of Simvastatin
por: Vree, Tom B., et al.
Publicado: (2003)

Excess ribosomal protein production unbalances translation in a model of Fragile X Syndrome
por: Seo, Sang S., et al.
Publicado: (2022)

Perturbed proteostasis in autism spectrum disorders
por: Louros, Susana R., et al.
Publicado: (2016)

Impaired Reliability and Precision of Spiking in Adults But Not Juveniles in a Mouse Model of Fragile X Syndrome
por: Dwivedi, Deepanjali, et al.
Publicado: (2019)

341 Repeats Is Not Enough for Methylation in a New Fragile X Mouse Model
por: Colvin, Steven, et al.
Publicado: (2022)

BC RNA Mislocalization in the Fragile X Premutation
por: Muslimov, Ilham A., et al.
Publicado: (2018)

Combining Lovastatin and Minocycline for the Treatment of Fragile X Syndrome: Results From the LovaMiX Clinical Trial
por: Champigny, Camille, et al.
Publicado: (2022)

Cell-Type Specific Channelopathies in the Prefrontal Cortex of the fmr1-/y Mouse Model of Fragile X Syndrome(1,2,3)
por: Kalmbach, Brian E., et al.
Publicado: (2015)

Clinical and Economic Outcomes of Conversion of Simvastatin to Lovastatin in a Group-Model Health Maintenance Organization
por: Billups, Sarah J., et al.
Publicado: (2005)

Impaired AMPARs Translocation into Dendritic Spines with Motor Skill Learning in the Fragile X Mouse Model
por: Suresh, Anand, et al.
Publicado: (2023)

GABA-B Agonist Baclofen Normalizes Auditory-Evoked Neural Oscillations and Behavioral Deficits in the Fmr1 Knockout Mouse Model of Fragile X Syndrome
por: Sinclair, D., et al.
Publicado: (2017)

Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome?
por: Lohith, Talakad G, et al.
Publicado: (2013)

A quantitative homogeneous assay for fragile X mental retardation 1 protein
por: Schutzius, Gabi, et al.
Publicado: (2013)

Mouse models of the fragile X premutation and fragile X-associated tremor/ataxia syndrome
por: Berman, Robert F, et al.
Publicado: (2014)

Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome
por: Thurman, Angela John, et al.
Publicado: (2020)

Mouse models of fragile X-related disorders
por: Willemsen, Rob, et al.
Publicado: (2023)

Biochemistry and Nanomechanical Properties of Human Colon Cells upon Simvastatin, Lovastatin, and Mevastatin Supplementations: Raman Imaging and AFM Studies
por: Beton, Karolina, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Simvastatin and Lovastatin/Extended-Release Niacin to Achieve LDL and HDL Goal Using NHANES Data
por: Armstrong, Edward P., et al.
Publicado: (2004)

Deficient Sleep in Mouse Models of Fragile X Syndrome
por: Saré, R. Michelle, et al.
Publicado: (2017)

Hyperexcitability of Sensory Neurons in Fragile X Mouse Model
por: Deng, Pan-Yue, et al.
Publicado: (2021)

The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells
por: Glynn, Sharon A, et al.
Publicado: (2008)

Vorinostat Corrects Cognitive and Non-Cognitive Symptoms in a Mouse Model of Fragile X Syndrome
por: Ding, Qi, et al.
Publicado: (2021)

Circuit-based intervention corrects excessive dentate gyrus output in the Fragile X mouse model
por: Deng, Pan-Yue, et al.
Publicado: (2023)

Sensory Processing Phenotypes in Fragile X Syndrome
por: Rais, Maham, et al.
Publicado: (2018)

Limbic Epileptogenesis in a Mouse Model of Fragile X Syndrome
por: Qiu, Li-Feng, et al.
Publicado: (2009)

FRAGILE X MENTAL RETARDATION PROTEIN REPLACEMENT RESTORES HIPPOCAMPAL SYNAPTIC FUNCTION IN A MOUSE MODEL OF FRAGILE X SYNDROME
por: Zeier, Zane, et al.
Publicado: (2009)

Timing of Expansion of Fragile X Premutation Alleles During Intergenerational Transmission in a Mouse Model of the Fragile X-Related Disorders
por: Zhao, Xiao-Nan, et al.
Publicado: (2018)

Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model
por: Naviaux, Jane C, et al.
Publicado: (2015)

Deficits in Tactile Learning in a Mouse Model of Fragile X Syndrome
por: Arnett, Megan T., et al.
Publicado: (2014)

Altered Gut Microbiota in a Fragile X Syndrome Mouse Model
por: Altimiras, Francisco, et al.
Publicado: (2021)

X-inactivation in the clinical phenotype of fragile X premutation carrier sisters
por: Hall, Deborah A., et al.
Publicado: (2016)

GABA(A) Alpha 2,3 Modulation Improves Select Phenotypes in a Mouse Model of Fragile X Syndrome
por: Schaefer, Tori L., et al.
Publicado: (2021)

Fragile X syndrome and fragile X-associated disorders
por: Rajaratnam, Akash, et al.
Publicado: (2017)

IFT81, encoding an IFT-B core protein, as a very rare cause of a ciliopathy phenotype
por: Perrault, Isabelle, et al.
Publicado: (2015)

Structural basis for the biosynthesis of lovastatin
por: Wang, Jialiang, et al.
Publicado: (2021)

Persistent astrocyte activation in the fragile X mouse cerebellum
por: Pacey, Laura K. K., et al.
Publicado: (2015)

Distinctive behavioral and cellular responses to fluoxetine in the mouse model for Fragile X syndrome
por: Uutela, Marko, et al.
Publicado: (2014)

Cerebral Protein Synthesis in a Knockin Mouse Model of the Fragile X Premutation
por: Qin, Mei, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dna0jh4726k8ncklcjk28p746b